Mitsubishi Tanabe rationalises manufacturing
This article was originally published in Scrip
Executive Summary
Japan's Mitsubishi Tanabe Pharma(MTP) is to merge its wholly owned production subsidiaries MP-Technopharma and Tanabe Seiyaku Yamaguchi on October 1st. The surviving entity will be Osaka-based MP Technopharma, which will employ around 800 people, although the plant run by the former Tanabe operation will continue to operate. The move, which will have only a minor financial impact, forms part of rationalisation steps following the October 2007 merger of Mitsubishi Pharma and Tanabe to form MTP, which said that it is considering the further restructuring of its manufacturing activities.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Genmab buys into ADCs; Roivant set to take on AbbVie in uveitis; Ipsen signs firs ADC pact; South Korea looks to build biotech momentum; and the end of the road for Acorda.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Merck & Co progresses cardiovascular strategy; Novo purchase builds heart failure presence; CRL setbacks for Regeneron; ITF faces challenging Duchenne field; and AbbVie needs to freshen up.